Étiquette : alcohol dependence

Bibliographie : Cannabidiol (CBD), Docteur Christian SUEUR, GRECC, février 2020.

Bibliographie : Cannabidiol (CBD) Docteur Christian SUEUR, GRECC, février 2020.     voir aussi : Bibliographie : Cannabis et Cannabinoïdes en Psychiatrie, Bibliographie : Cannabinoïdes et neuroprotection Bibliographie : Cannabinoïdes et épilepsie Bibliographie : Interactions et antagonisme THC - CBD Bibliographie : Effets indésirables du Cannabis (thérapeutique) sur la Santé mentale Bibliographie : Cannabinoïdes, Dépression et Troubles de l’Humeur Bibliographie : Cannabinoïdes et PTSD Bibliographie : Cannabinoïdes et TSA/TED/psychoses infantiles Bibliographie : Cannabinoïdes et Maladies Neurodégénératives

Lire la suite

Le cannabidiol, un agent thérapeutique prometteur ?, Benjamin Rolland et al., 2019

Le cannabidiol, un agent thérapeutique prometteur ? Benjamin Rolland , Mathieu Chappuy, Patrizia Carrieri SWAPS, 3e et 4e trimestre 2019, n° 92-93, , 5-6.   Deuxième cannabinoïde le plus étudié après le THC, sans effet psychoactif, le cannabidiol dispose de propriétés thérapeutiques intéressantes, notamment en psychiatrie. Le point sur les recherches La grande famille des cannabinoïdes Les cannabinoïdes sont un ensemble de substances capables d’activer les récepteurs du même nom (« récepteurs cannabinoïdes »). Il existe deux grandes familles de récepteurs cannabinoïdes, CB1 et CB2. Dans le système nerveux central, c’est surtout CB1 qui est exprimé, alors que CB2 est principalement présent dans le système immunitaire. [...]

Lire la suite

Psilocybin-Assisted Therapy : A Review of a Novel Treatment for Psychiatric Disorders, Kelan Thomas et al., 2017

Psilocybin-Assisted Therapy : A Review of a Novel Treatment for Psychiatric Disorders Kelan Thomas, Pharm.D., M.S., Benjamin Malcolm, Pharm.D., M.P.H., and Dan Lastra, B.S. Journal of Psychoactive Drugs, 2017 Doi : 10.1080/02791072.2017.1320734   Abstract Recent research suggests that functional connectivity changes may be involved in the pathophysiology of psychiatric disorders. Hyperconnectivity in the default mode network has been associated with psycho-pathology, but psychedelic serotonin agonists like psilocybin may profoundly disrupt these dysfunctional neural network circuits and provide a novel treatment for psychiatric disorders. We have reviewed the current literature to investigate the efficacy and safety of psilocybin-assisted therapy for the treatment of psychiatric disorders. There were [...]

Lire la suite

Single Shot of Ketamine May Herald ‘Last Call’ for Problem Drinking, Deborah Brauser, 2019

Single Shot of Ketamine May Herald 'Last Call' for Problem Drinking Deborah Brauser Medscape, December 11, 2019 Medscape Medical News © 2019 https://www.medscape.com/viewarticle/922460?src=wnl_tp10n_200116_mscpedit&uac=292598PZ&impID=2238619&faf=1   An experimental treatment that includes a single infusion of ketamine may lead to long-term improvement in problem drinking, new research suggests. In an study of 90 heavy drinkers, those who received a single dose of intravenous (IV) ketamine plus cognitive behavioral therapy (CBT) that focused on reactivating drinking-related "maladaptive reward memories" (MRMs) significantly curbed the urge to drink and reduced alcohol intake  compared with those who received the ketamine alone or a placebo infusion. In addition, the combination group reduced their average weekly alcohol consumption by [...]

Lire la suite

Soigner l’alcoolisme et la dépression avec des psychédéliques ? Entretien avec David Nutt, video, 2019

Soigner l'alcoolisme et la dépression avec des psychédéliques? Entretien avec David Nutt #RTSsanté , 11 avril 2019 https://www.youtube.com/watch?time_continue=55&v=D8QNY2bdNCk&feature=emb_logo Vidéo en complément du reportage « Le retour des psychédéliques » : https://youtu.be/503cSLA0Z38   Parmi les très nombreux articles cosignés par le Professeur David J. NUTT, du Psychedelic Research Group, Department of Medicine, Imperial College London, London, United Kingdom, les références suivantes sont disponibles sur le site du GRECC :   Dissociable effects of cannabis with and without cannabidiol on the human brain’s resting-state functional connectivity, Matthew B. Wall, Rebecca Pope, Tom P. Freeman, Oliwia S. Kowalczyk, Lysia Demetriou, Claire Mokrysz, Chandni Hindocha, Will Lawn, Michael A.P. Bloomfield, Abigail M. [...]

Lire la suite

Associations of Parental Marijuana Use With Offspring Marijuana, Tobacco, and Alcohol Use and Opioid Misuse, Bertha K. Madras et al, 2019

Associations of Parental Marijuana Use With Offspring Marijuana, Tobacco, and Alcohol Use and Opioid Misuse Bertha K. Madras, Beth Han, Wilson M. Compton, Christopher M. Jones, Elizabeth I. Lopez, Elinore F. McCance-Katz JAMA Network Open, 2019, 2, (11), e1916015. doi : 10.1001/jamanetworkopen.2019.16015   Abstract IMPORTANCE : Marijuana use is increasing among adults and often co-occurs with other substance use; therefore, it is important to examine whether parental marijuana use is associated with elevated risk of substance use among offspring living in the same household. OBJECTIVE : To examine associations of parental marijuana use with offspring marijuana, tobacco, and alcohol use and opioid misuse. DESIGN, SETTING, AND PARTICIPANTS : [...]

Lire la suite

Prevalence and Correlates of Cannabis Use in Outpatients with Serious Mental Illness receiving treatment for Alcohol Use Disorders, Jordan Skalisky et al., 2017

Prevalence and Correlates of Cannabis Use in Outpatients with Serious Mental Illness receiving treatment for Alcohol Use Disorders Jordan Skalisky, Emily Leickly, Oladunni Oluwoye, Sterling M. McPherson, Debra Srebnik, John M. Roll, Richard K. Ries, and Michael G. McDonell Cannabis and Cannabinoid Research, 2017, 2, 1, 133-138. Doi : 10.1089/can.2017.0006   Abstract Introduction : People with serious mental illness (SMI) use cannabis more than any other illicit drug. Cannabis use is associated with increased psychotic symptoms and is highly comorbid with alcohol use disorders (AUDs). Despite the national trend toward decriminalization, little is known about the prevalence, correlates, and impact of cannabis use on those with SMI [...]

Lire la suite

Transdermal Delivery of Cannabidiol Attenuates Binge Alcohol- Induced Neurodegeneration in a Rodent Model of an Alcohol Use Disorder, Daniel J. Liput et al., 2013

Transdermal Delivery of Cannabidiol Attenuates Binge Alcohol- Induced Neurodegeneration in a Rodent Model of an Alcohol Use Disorder Daniel J. Liput, Dana C. Hammell, Audra L. Stinchcomb, and Kimberly Nixon Pharmacology, Biochemistry and  Behavior, 2013, 111, 120–127. doi : 10.1016/j.pbb.2013.08.013   Abstract Excessive alcohol consumption, characteristic of alcohol use disorders, results in neurodegeneration and behavioral and cognitive impairments that are hypothesized to contribute to the chronic and relapsing nature of alcoholism. Therefore, the current study aimed to advance the preclinical development of transdermal delivery of cannabidiol (CBD) for the treatment of alcohol-induced neurodegeneration. In experiment 1, 1.0%, 2.5% and 5.0% CBD gels were evaluated for neuroprotection. [...]

Lire la suite

Psychiatry & the psychedelic drugs. Past, present & future, James J.H. Rucker et al., 2018

Psychiatry & the psychedelic drugs. Past, present & future James J.H. Rucker, Jonathan Iliff, David J. Nutt Neuropharmacology, 2018, 142, 200e218 https://doi.org/10.1016/j.neuropharm.2017.12.040   a b s t r a c t The classical psychedelic drugs, including psilocybin, lysergic acid diethylamide and mescaline, were used extensively in psychiatry before they were placed in Schedule I of the UN Convention on Drugs in 1967. Experimentation and clinical trials undertaken prior to legal sanction suggest that they are not helpful for those with established psychotic disorders and should be avoided in those liable to develop them. However, those with so-called ‘psychoneurotic’ disorders sometimes benefited considerably from their tendency to [...]

Lire la suite

Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings, Sonja ELSAID, 2019

Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings. Molecular Basis of Neuropsychiatric Disorders : from Bench to Bedside Sonja ELSAID, Stefan KLOIBER, Bernard Le FOLL Progress in Molecular Biology and Translational Science, 2019, 167, 25-75. doi : 10.1016/bs.pmbts.2019.06.005. Cannabis sativa (cannabis) is on of the oldest plants cultivated by men. Cannabidiol (CBD) is the major non-psychomimetic compound derived from cannabis. It has been proposed to have a therapeutic potential over a wide range of neuropsychiatric disorders. In this narrative review, we have summarized a selected number of pre-clinical and clinical studies, examining the effects of CBD in neuropsychiatric [...]

Lire la suite